Skip to main content

Advertisement

Table 6 Adverse events in patients treated as adjuvant/first-line setting (n = 32)

From: Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients

Adverse event G0 G1 G2 G3 G4 NE All grades (%) Grade 3/4 (%)
Leucocyte 3 3 8 10 7 1 87.5 53.1
Neutrophils 2 3 5 8 13 1 90.6 65.6
Hemoglobin 10 8 8 5 0 1 65.6 15.6
Platelets 19 3 6 3 0 1 37.5 9.4
AST 22 6 2 1 0 1 28.1 3.1
ALT 22 5 1 3 0 1 28.1 9.4
Anorexia 13 14 5 0 0 0 59.4 0.0
Nausea 17 11 4 0 0 0 46.9 0.0
Vomiting 26 5 1 0 0 0 18.8 0.0
Diarrhea 26 4 1 1 0 0 18.8 3.1
Fatigue 14 12 5 1 0 0 56.3 3.1
Febrile neutropenia 29 0 0 3 0 0 9.4 9.4
Fever 24 6 1 1 0 0 25.0 3.1
Infection 29 0 1 2 0 0 9.4 6.3
Dyspnea 31 0 0 1 0 0 3.1 3.1
Interstitial pneumonia 30 2 0 0 0 0 6.3 0.0
Neuropathy 32 0 0 0 0 0 0.0 0.0
Rash 24 4 3 1 0 0 25.0 3.1
Edema 30 2 0 0 0 0 6.3 0.0
Mucositis 31 0 1 0 0 0 3.1 0.0
Allergic reaction 32 0 0 0 0 0 0.0 0.0
  1. AST aspartate transaminase, ALT alanine aminotransferase